TWEAK Receptor/Fn14 Antibody #4403
- WB
- IP
Supporting Data
| REACTIVITY | H M R B |
| SENSITIVITY | Endogenous |
| MW (kDa) | 14-17 |
| SOURCE | Rabbit |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
- B-Bovine
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
Storage
Protocol
Specificity / Sensitivity
TWEAK Receptor/Fn14 Antibody detects endogenous levels of total TWEAK Receptor/Fn14 protein.
Species Reactivity:
Human, Mouse, Rat, Bovine
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of the TWEAK Receptor/Fn14. Antibodies were purified by protein A and peptide affinity chromatography.
Background
The receptor for TWEAK, fibroblast growth factor-inducible 14 (Fn14), is a member of the TNF superfamily of receptors thought to be involved in cell growth, adhesion and migration (1). Its expression is regulated by a number of different growth factors (1,2). Elevated expression is also seen in some cancers including hepatocellular carcinomas (3), glioblastomas (4), and pancreatic cancer (5). The receptor contains a binding site for members of the TNFR-associated factor (TRAF) family that promotes the activation of NF-κB (1,6). Recent studies have suggested some therapeutic potential of TWEAK and its receptor signaling in regards to autoimmunity and cancer treatment (7-9).
- Wiley, S.R. et al. (2001) Immunity 15, 837-46.
- Nakayama, M. et al. (2003) J. Immunol. 170, 341-8.
- Feng, S.L. et al. (2000) Am. J. Pathol. 156, 1253-61.
- Tran, N.L. et al. (2003) Am. J. Pathol. 162, 1313-21.
- Han, H. et al. (2002) Cancer Res. 62, 2890-6.
- Brown, S.A. et al. (2003) Biochem J. 371, 395-403.
- Desplat-Jégo, S. et al. (2005) Clin. Immunol. 117, 15-23.
- Mueller, A.M. et al. (2005) J. Neuroimmunol. 159, 55-65.
- Winkles, J.A. et al. (2006) Cancer Lett 235, 11-7.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.